Consistent with previous drug prediction analyses, bromodomain inhibitor OTX015 has great therapeutic potential in MM with the ability to modulate NF-κB, cell cycle, EGFR, and proliferative signaling pathways (102). This evidence concerns the gene NFKB1 and Miyoshi myopathy.